Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel <i>LDLR-ROS1</i> Fusion. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.